3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Noonan Syndrome 6
1
Neuroblastoma
1
Melanoma
1
Malignant Non-small Cell Neoplasm of Lung Stage IV
1
Lymphoproliferative Disorders
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Doxorubicin
69
Radiotherapy
50
Ifosfamide
48
Gemcitabine
43
Cyclophosphamide
36
pazopanib
29
Filgrastim
28
pembrolizumab
26
Docetaxel
26
Nivolumab
23
Surgical Procedures, Operative
21
Etoposide
21
Cisplatin
21
Trabectedin
19
Blood Specimen Collection
19
Carboplatin
15
Radiation
14
Magnetic Resonance Spectroscopy
14
Vincristine
13
Bevacizumab
13
anlotinib
12
Temozolomide
12
Peripheral Blood Stem Cell Transplantation
12
Ipilimumab
12
liposomal doxorubicin
11
apatinib
11
Radiosurgery
11
Neoadjuvant Therapy
11
Melphalan
11
Surveys and Questionnaires
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled